
Commentary|Videos|March 16, 2026
Deescalation vs Intensification: How to Ensure Patients Get the Treatment They Need
Author(s)Hua-Jay "Jeff" Cherng, MD
Fact checked by: Paige Britt
MRD testing personalizes diffuse large B‑cell lymphoma therapy—shorten chemo for early responders and flag high‑risk patients for targeted add‑ons.
In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discussed how to ensure patients with lymphoma receive the proper level of treatment based on molecular response in clinical trials.




























